Tradestie Institutional Equity Comparison Engine
VRXA vs YDES โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
YDES Overall Edge
YDES Captures Institutional Edge (2โ0 Pillars ยท 7โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to YD Bio Limited Ordinary Shares (YDES) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, VRXA trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus YDES at N/M Forward P/E and -528.7% operating margin (+314.9% YoY). In options structure, VRXA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against YDES sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
VRXA N/M vs YDES N/M Fwd P/E
Growth & Margin Winner
YDES
Op Margin N/A vs -528.7% ยท YoY N/A vs +314.9%
Momentum & Technical Winner
YDES
1Y -95.8% vs -48.1% ยท 52W Pos 0% vs 22%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
VRXA
US Equity
VRXA
Institutional Equity
$1.04
+0.97% 1D
Market Cap
N/A
1M Return
+0.97%
1Y Return
-95.8%
Forward P/E
N/M
Unified AI Score
41.6 / 100
SELL
Tech 30.0
Fund 41.0
Flow 50.0
Mom 54.0
YDES
NASDAQ
YD Bio Limited Ordinary Shares
Services-Medical Laboratories
$4.83
+5.92% 1D
Market Cap
$323.0M
1M Return
+13.92%
1Y Return
-48.06%
Forward P/E
N/M
Unified AI Score
49.0 / 100
HOLD
Tech 31.0
Fund 35.0
Flow 50.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
VRXA -95.8%
YDES -48.06%
Spread: +144.42 pp (YDES Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
VRXA TTM Op. Margin: N/A
YDES TTM Op. Margin: -528.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VRXA vs YDES. Trailing 12-month operating profitability (VRXA N/A vs YDES -528.7%) and valuation multiples (VRXA N/M vs YDES N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VRXA | YDES | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $323.0M | Larger Scale | YDES |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | +314.9% | Higher Growth | YDES |
| Operating Margin (TTM) Profitability | N/A | -528.7% | Higher Margin | YDES |
| Net Profit Margin Profitability | N/A | 24.7% | Higher Margin | YDES |
| Return on Equity (ROE) Capital Efficiency | N/A | -42.7% | Higher ROE | YDES |
| 52-Week Range Position Momentum | 0% ($1โ$27) | 22% ($2โ$16) | Stronger Trend | YDES |
| Beta / 30D Volatility Risk Regime | 1.16ฮฒ ยท 104% Vol | -0.07ฮฒ ยท 139% Vol | Lower Realized Risk | VRXA |
| Unified Institutional Score Composite Signal | 41.6 / 100 (SELL) | 49.0 / 100 (HOLD) | Higher Composite | YDES |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full VRXA vs YDES Buy Guide
VRXA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
YDES
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither VRXA nor YDES registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.